Medicine
Methotrexate Toxicity in Psoriasis: Folate Supplementation and Drug Interactions
Quick fact
Supplementing with folic acid—just 1–5 mg daily—can reduce methotrexate’s common toxicities (nausea, liver enzyme elevations, and blood count drops) by up to 80% without diminishing its effectiveness against psoriasis.
Why this is interesting
Methotrexate can be a miracle for severe psoriasis, but without careful management, it can silently damage the liver and bone marrow. Why do some patients get serious side effects while others thrive?
Read the full explanation
Understanding Methotrexate Toxicity in Psoriasis: Folate Supplementation and Drug Interactions
Methotrexate treats psoriasis by inhibiting an enzyme called dihydrofolate reductase, which is essential for activating folate (vitamin B9) into its usable form. Active folate is needed to make DNA, especially in rapidly dividing cells like skin cells and immune cells. By slowing down those cells, methotrexate reduces the inflammation and scaling of psoriasis. But the same mechanism can harm healthy fast-dividing cells—like those in the bone marrow (making blood cells) and the lining of the gut—and can stress the liver. Folate supplementation works by replenishing the body’s folate pool. Since methotrexate blocks the enzyme, giving extra folate helps supply the needed active form indirectly, because the blockade is incomplete and can be overcome with higher concentrations. Clinical trials show that folic acid (usually 1–5 mg daily, sometimes 5 mg once weekly, skipped on the day of methotrexate dose) reduces side effects like nausea, fatigue, and hair loss, as well as liver enzyme elevations and blood count abnormalities. Interestingly, it does not reduce methotrexate’s beneficial effect on psoriasis—the reduction in skin symptoms remains the same. Drug interactions add another layer. Some medications can increase methotrexate toxicity. For example: trimethoprim (an antibiotic) also inhibits folate metabolism, and when combined with methotrexate, it can cause severe bone marrow suppression. NSAIDs (like ibuprofen) can reduce the kidney’s clearance of methotrexate, raising its blood levels. Penicillins can also reduce renal clearance. Therefore, it’s crucial to review a patient’s medication list and avoid these combinations, or adjust dosing if they are necessary.
A deeper explanation
The core mechanism of methotrexate toxicity is its reversible, competitive inhibition of dihydrofolate reductase (DHFR). This enzyme converts dietary folic acid into tetrahydrofolate (THF), the active form, which is a crucial donor of one-carbon units in the synthesis of thymidylate and purines—building blocks of DNA. When DHFR is blocked, cells that divide rapidly (e.g., bone marrow progenitors, intestinal crypt cells, and psoriatic keratinocytes) run out of thymidine, leading to impaired DNA synthesis and cell death. The selectivity of methotrexate for rapidly dividing cells explains why the bone marrow and gastrointestinal tract are common sites of toxicity. The liver is also affected, but through a different pathway: methotrexate and its metabolites can accumulate in hepatocytes, causing oxidative stress and fibrosis, especially with chronic use. Folate supplementation counteracts this by increasing the intracellular pool of reduced folates, which can compete with methotrexate for DHFR binding and provide substrate for continued DNA synthesis. The timing of supplementation (avoiding the day of methotrexate dose) is based on pharmacokinetic principles: giving folic acid on the same day may interfere with methotrexate’s efficacy, though evidence suggests that even daily dosing is safe and effective. The reduction in toxicity is substantial, and it does not compromise the therapeutic response, likely because psoriatic skin and immune cells are more sensitive to methotrexate than normal cells under these conditions. Drug interactions multiply the risk. Trimethoprim, used for urinary infections, is also a DHFR inhibitor, albeit weaker. Combined with methotrexate, it creates a synergistic blockade of folate metabolism, leading to severe pancytopenia. NSAIDs reduce renal blood flow and compete with methotrexate for tubular secretion, reducing its excretion and increasing blood levels, which can lead to toxicity. Penicillins can similarly reduce renal clearance. Therefore, prescribers must screen for these interactions and consider alternative antibiotics or analgesics, or dose-adjust methotrexate accordingly. Understanding these mechanisms allows clinicians to prevent toxicity by using the lowest effective methotrexate dose, prescribing folate supplementation, and carefully monitoring blood counts and liver function. It also empowers patients to recognize signs of toxicity early and to report them promptly. In essence, methotrexate therapy in psoriasis is a balance: harness the therapeutic benefit while protecting the body’s healthy dividing cells and liver through co-interventions and vigilant monitoring.